Table of Contents Author Guidelines Submit a Manuscript
Sarcoma
Volume 2017, Article ID 7429697, 10 pages
https://doi.org/10.1155/2017/7429697
Review Article

Malignant Peripheral Nerve Sheath Tumors State of the Science: Leveraging Clinical and Biological Insights into Effective Therapies

1Center for Cancer and Blood Disorders, Children’s National Health System, 111 Michigan Ave NW, Washington, DC 20010, USA
2Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, 9609 Medical Center Drive, Room 6E450, Bethesda, MD 20892, USA
3Rare Tumors Initiative, OD, CCR, National Cancer Institute, 37 Convent Drive, Bethesda, MD 20814, USA
4University of Utah, 295 Chipeta Way, Salt Lake City, UT 84108, USA
5Center for Cancer Research, National Cancer Institute, 10 Center Drive, Room 2S235C, Building 10, Bethesda, MD 20892, USA
6National Cancer Institute, Pediatric Oncology Branch, 10 Center Drive, Room 1-3742, Building 10, Bethesda, MD 20892, USA

Correspondence should be addressed to AeRang Kim; gro.lanoitansnerdlihc@mikea

Received 6 February 2017; Accepted 3 April 2017; Published 16 May 2017

Academic Editor: Alexander Lazar

Copyright © 2017 AeRang Kim et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. E. Ferner, “Neurofibromatosis 1 and neurofibromatosis 2: a twenty first century perspective,” The Lancet Neurology, vol. 6, no. 4, pp. 340–351, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. D. G. R. Evans, M. E. Baser, J. McGaughran, S. Sharif, E. Howard, and A. Moran, “Malignant peripheral nerve sheath tumours in neurofibromatosis,” Journal of Medical Genetics, vol. 39, no. 5, pp. 311–314, 2002. View at Publisher · View at Google Scholar · View at Scopus
  3. E. Uusitalo, M. Rantanen, R. A. Kallionpää et al., “Distinctive cancer associations in patients with neurofibromatosis type 1,” Journal of Clinical Oncology, vol. 34, no. 17, pp. 1978–1986, 2016. View at Publisher · View at Google Scholar
  4. H. Meany, B. C. Widemann, and N. Ratner, “Malignant peripheral nerve sheath tumors: prognostic and diagnostic markers and therapeutic targets,” in Neurofibromatosis Type 1, pp. 445–467, Springer, Berlin, Germany, 2012. View at Google Scholar
  5. C. L. Scaife and P. W. T. Pisters, “Combined-modality treatment of localized soft tissue sarcomas of the extremities,” Surgical Oncology Clinics of North America, vol. 12, no. 2, pp. 355–368, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. P. W. Pisters, D. H. Leung, J. Woodruff, W. Shi, and M. F. Brennan, “Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities,” Journal of Clinical Oncology, vol. 14, no. 5, pp. 1679–1689, 1996. View at Publisher · View at Google Scholar · View at Scopus
  7. G. Gupta, A. Mammis, and A. Maniker, “Malignant peripheral nerve sheath tumors,” Neurosurgery Clinics of North America, vol. 19, no. 4, pp. 533–543, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. R. E. Ferner and D. H. Gutmann, “International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis,” Cancer Research, vol. 62, no. 5, pp. 1573–1577, 2002. View at Google Scholar · View at Scopus
  9. V.-F. Mautner, F. A. Asuagbor, E. Dombi et al., “Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1,” Neuro-Oncology, vol. 10, no. 4, pp. 593–598, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Kim, A. Gillespie, E. Dombi et al., “Characteristics of children enrolled in treatment trials for NF1-related plexiform neurofibromas,” Neurology, vol. 73, no. 16, pp. 1273–1279, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. J. Wasa, Y. Nishida, S. Tsukushi et al., “MRI features in the differentiation of malignant peripheral nerve sheath tumors and neurofibromas,” American Journal of Roentgenology, vol. 194, no. 6, pp. 1568–1574, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Matsumine, K. Kusuzaki, T. Nakamura et al., “Differentiation between neurofibromas and malignant peripheral nerve sheath tumors in neurofibromatosis 1 evaluated by MRI,” Journal of Cancer Research and Clinical Oncology, vol. 135, no. 7, pp. 891–900, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. R. E. Ferner, J. F. Golding, M. Smith et al., “[18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study,” Annals of Oncology, vol. 19, no. 2, pp. 390–394, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. S. M. Broski, G. B. Johnson, B. M. Howe et al., “Evaluation of 18F-FDG PET and MRI in differentiating benign and malignant peripheral nerve sheath tumors,” Skeletal Radiology, vol. 45, no. 8, pp. 1097–1105, 2016. View at Publisher · View at Google Scholar · View at Scopus
  15. E. Dombi, S. L. Ardern-Holmes, D. Babovic-Vuksanovic et al., “Recommendations for imaging tumor response in neurofibromatosis clinical trials,” Neurology, vol. 81, no. 21, supplement 1, pp. S33–S40, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. E. Dombi, J. Solomon, A. J. Gillespie et al., “NF1 plexiform neurofibroma growth rate by volumetric MRI: relationship to age and body weight,” Neurology, vol. 68, no. 9, pp. 643–647, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. D. H. Gutmann, J. O. Blakeley, B. R. Korf, and R. J. Packer, “Optimizing biologically targeted clinical trials for neurofibromatosis,” Expert Opinion on Investigational Drugs, vol. 22, no. 4, pp. 443–462, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. J. Solomon, K. Warren, E. Dombi, N. Patronas, and B. Widemann, “Automated detection and volume measurement of plexiform neurofibromas in neurofibromatosis 1 using magnetic resonance imaging,” Computerized Medical Imaging and Graphics, vol. 28, no. 5, pp. 257–265, 2004. View at Publisher · View at Google Scholar · View at Scopus
  19. R. Nguyen, E. Dombi, B. C. Widemann et al., “Growth dynamics of plexiform neurofibromas: a retrospective cohort study of 201 patients with neurofibromatosis 1,” Orphanet Journal of Rare Diseases, vol. 7, article 75, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Akshintala, S. Bhaumik, A. Venkatesan et al., “Identification of lesions concerning for transformation to malignant peripheral nerve sheath tumors (MPNST) in Neurofibromatosis 1 (NF1),” in Radiological Society of North America, 2014. View at Google Scholar
  21. H. Meany, E. Dombi, J. Reynolds et al., “18-fluorodeoxyglucose-positron emission tomography (FDG-PET) evaluation of nodular lesions in patients with neurofibromatosis type 1 and plexiform neurofibromas (PN) or malignant peripheral nerve sheath tumors (MPNST),” Pediatric Blood and Cancer, vol. 60, no. 1, pp. 59–64, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. C. Higham, E. Legius, N. Ullrich et al., Atypical Neurofibromas in NF1: Clinical, Imaging and Pathology Characteristics, Children's Tumor Foundation, Austin, Tex, USA, 2016.
  23. E. Beert, H. Brems, B. Daniëls et al., “Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumors,” Genes Chromosomes and Cancer, vol. 50, no. 12, pp. 1021–1032, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. F. J. Rodriguez, A. L. Folpe, C. Giannini, and A. Perry, “Pathology of peripheral nerve sheath tumors: diagnostic overview and update on selected diagnostic problems,” Acta Neuropathologica, vol. 123, no. 3, pp. 295–319, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. B. Widemann, S. Bhaumik, S. Akshintala et al., “Identification of lesions concenring for malignant peripheral nerve sheath tumors in NF1,” in Proceedings of the CTOS Members Business Meeting, Salt Lake City, Utah, USA, 2015.
  26. N. M. Bernthal, A. Putnam, K. B. Jones, D. Viskochil, and R. L. Randall, “The effect of surgical margins on outcomes for low grade MPNSTs and atypical neurofibroma,” Journal of Surgical Oncology, vol. 110, no. 7, pp. 813–816, 2014. View at Publisher · View at Google Scholar · View at Scopus
  27. C. D. M. Fletcher, K. K. Unni, and F. Mertens, WHO Classification of Tumours of Soft Tissue and Bone, IARC, Lyons, France, 4th edition, 2013.
  28. B. W. Scheithauer, J. M. Woodruff, and R. A. Erlandson, Tumors of the Peripheral Nervous System, Atlas of Tumor Pathology Third Series, Armed Forces Institute of Pathology, Washington, DC, USA, 1999.
  29. M. Pekmezci, D. E. Reuss, A. C. Hirbe et al., “Morphologic and immunohistochemical features of malignant peripheral nerve sheath tumors and cellular schwannomas,” Modern Pathology, vol. 28, no. 2, pp. 187–200, 2015. View at Publisher · View at Google Scholar · View at Scopus
  30. M. Zhang, Y. Wang, S. Jones et al., “Somatic mutations of SUZ12 in malignant peripheral nerve sheath tumors,” Nature Genetics, vol. 46, no. 11, pp. 1170–1172, 2014. View at Publisher · View at Google Scholar · View at Scopus
  31. A. C. Hirbe, S. Dahiya, C. A. Miller et al., “Whole exome sequencing reveals the order of genetic changes during malignant transformation and metastasis in a single patient with NF1-plexiform neurofibroma,” Clinical Cancer Research, vol. 21, no. 18, pp. 4201–4211, 2015. View at Publisher · View at Google Scholar · View at Scopus
  32. S. L. Carroll, “The challenge of cancer genomics in rare nervous system neoplasms: malignant peripheral nerve sheath tumors as a paradigm for cross-species comparative oncogenomics,” American Journal of Pathology, vol. 186, no. 3, pp. 464–477, 2016. View at Publisher · View at Google Scholar · View at Scopus
  33. H. Li, S. Velasco-Miguel, W. C. Vass, L. F. Parada, and J. E. DeClue, “Epidermal growth factor receptor signaling pathways are associated with tumorigenesis in the Nf1:p53 mouse tumor model,” Cancer Research, vol. 62, no. 15, pp. 4507–4513, 2002. View at Google Scholar · View at Scopus
  34. T. De Raedt, E. Beert, E. Pasmant et al., “PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies,” Nature, vol. 514, no. 7521, pp. 247–251, 2014. View at Publisher · View at Google Scholar · View at Scopus
  35. W. Lee, S. Teckie, T. Wiesner et al., “PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors,” Nature Genetics, vol. 46, no. 11, pp. 1227–1232, 2014. View at Publisher · View at Google Scholar · View at Scopus
  36. T. De Raedt, H. Brems, P. Wolkenstein et al., “Elevated risk for MPNST in NF1 microdeletion patients,” American Journal of Human Genetics, vol. 72, no. 5, pp. 1288–1292, 2003. View at Publisher · View at Google Scholar · View at Scopus
  37. A. H. G. Cleven, G. A. Al Sannaa, I. Briaire-de Bruijn et al., “Loss of H3K27 tri-methylation is a diagnostic marker for malignant peripheral nerve sheath tumors and an indicator for an inferior survival,” Modern Pathology, vol. 29, no. 6, pp. 582–590, 2016. View at Publisher · View at Google Scholar · View at Scopus
  38. C. N. Prieto-Granada, T. Wiesner, J. L. Messina, A. A. Jungbluth, P. Chi, and C. R. Antonescu, “Loss of H3K27me3 expression is a highly sensitive marker for sporadic and radiation-induced MPNST,” The American Journal of Surgical Pathology, vol. 40, no. 4, pp. 479–489, 2016. View at Publisher · View at Google Scholar · View at Scopus
  39. M. Röhrich, C. Koelsche, D. Schrimpf et al., “Methylation-based classification of benign and malignant peripheral nerve sheath tumors,” Acta Neuropathologica, vol. 131, no. 6, pp. 877–887, 2016. View at Publisher · View at Google Scholar
  40. J. E. DeClue, A. G. Papageorge, J. A. Fletcher et al., “Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis,” Cell, vol. 69, no. 2, pp. 265–273, 1992. View at Publisher · View at Google Scholar · View at Scopus
  41. J. J. Ryan, K. A. Klein, T. J. Neuberger et al., “Role for the stem cell factor/KIT complex in schwann cell neoplasia and mast cell proliferation associated with neurofibromatosis,” Journal of Neuroscience Research, vol. 37, no. 3, pp. 415–432, 1994. View at Publisher · View at Google Scholar · View at Scopus
  42. A. Badache, N. Muja, and G. H. De Vries, “Expression of Kit in neurofibromin-deficient human Schwann cells: role in Schwann cell hyperplasia associated with type 1 neurofibromatosis,” Oncogene, vol. 17, no. 6, pp. 795–800, 1998. View at Publisher · View at Google Scholar · View at Scopus
  43. J. E. DeClue, S. Heffelfinger, G. Benvenuto et al., “Epidermal growth factor receptor expression in neurofibromatosis type 1-related tumors and NF1 animal models,” The Journal of Clinical Investigation, vol. 105, no. 9, pp. 1233–1241, 2000. View at Publisher · View at Google Scholar · View at Scopus
  44. I. Dang and G. H. DeVries, “Schwann cell lines derived from malignant peripheral nerve sheath tumors respond abnormally to platelet-derived growth factor-BB,” Journal of Neuroscience Research, vol. 79, no. 3, pp. 318–328, 2005. View at Publisher · View at Google Scholar · View at Scopus
  45. N. Holtkamp, A. F. Okuducu, J. Mucha et al., “Mutation and expression of PDGFRA and KIT in malignant peripheral nerve sheath tumors, and its implications for imatinib sensitivity,” Carcinogenesis, vol. 27, no. 3, pp. 664–671, 2006. View at Publisher · View at Google Scholar · View at Scopus
  46. M. Hakozaki, H. Hojo, M. Sato et al., “Establishment and characterization of a novel human malignant peripheral nerve sheath tumor cell line, FMS-1, that overexpresses epidermal growth factor receptor and cyclooxygenase-2,” Virchows Archiv, vol. 455, no. 6, pp. 517–526, 2009. View at Publisher · View at Google Scholar · View at Scopus
  47. K. E. Torres, Q.-S. Zhu, K. Bill et al., “Activated MET is a molecular prognosticator and potential therapeutic target for malignant peripheral nerve sheath tumors,” Clinical Cancer Research, vol. 17, no. 12, pp. 3943–3955, 2011. View at Publisher · View at Google Scholar · View at Scopus
  48. J. M. Eckert, S. J. Byer, B. J. Clodfelder-Miller, and S. L. Carroll, “Neuregulin-1β and neuregulin-1α differentially affect the migration and invasion of malignant peripheral nerve sheath tumor cells,” GLIA, vol. 57, no. 14, pp. 1501–1520, 2009. View at Publisher · View at Google Scholar · View at Scopus
  49. C. Friedrich, N. Holtkamp, J. Cinatl Jr. et al., “Overexpression of Midkine in malignant peripheral nerve sheath tumor cells inhibits apoptosis and increases angiogenic potency,” International Journal of Oncology, vol. 27, no. 5, pp. 1433–1440, 2005. View at Google Scholar · View at Scopus
  50. M. Demestre, M. Y. Terzi, V. Mautner, P. Vajkoczy, A. Kurtz, and A. L. Piña, “Effects of pigment epithelium derived factor (PEDF) on malignant peripheral nerve sheath tumours (MPNSTs),” Journal of Neuro-Oncology, vol. 115, no. 3, pp. 391–399, 2013. View at Publisher · View at Google Scholar · View at Scopus
  51. H. Sonobe, T. Takeuchi, M. Furihata et al., “A new human malignant peripheral nerve sheath tumour-cell line, HS-sch-2, harbouring p53 point mutation,” International Journal of Oncology, vol. 17, no. 2, pp. 347–352, 2000. View at Google Scholar · View at Scopus
  52. N. Holtkamp, I. Atallah, A.-F. Okuducu et al., “MMP-13 and p53 in the progression of malignant peripheral nerve sheath tumors,” Neoplasia, vol. 9, no. 8, pp. 671–677, 2007. View at Publisher · View at Google Scholar · View at Scopus
  53. M. Gong, J. Ma, M. Li, M. Zhou, J. M. Hock, and X. Yu, “MicroRNA-204 critically regulates carcinogenesis in malignant peripheral nerve sheath tumors,” Neuro-Oncology, vol. 14, no. 8, pp. 1007–1017, 2012. View at Publisher · View at Google Scholar · View at Scopus
  54. G. Q. Perrin, H. Li, L. Fishbein et al., “An orthotopic xenograft model of intraneural NF1 MPNST suggests a potential association between steroid hormones and tumor cell proliferation,” Laboratory Investigation, vol. 87, no. 11, pp. 1092–1102, 2007. View at Publisher · View at Google Scholar · View at Scopus
  55. P. Bhola, S. Banerjee, J. Mukherjee et al., “Preclinical in vivo evaluation of rapamycin in human malignant peripheral nerve sheath explant xenograft,” International Journal of Cancer, vol. 126, no. 2, pp. 563–571, 2010. View at Publisher · View at Google Scholar · View at Scopus
  56. S. J. Byer, J. M. Eckert, N. M. Brossier et al., “Tamoxifen inhibits malignant peripheral nerve sheath tumor growth in an estrogen receptor-independent manner,” Neuro-Oncology, vol. 13, no. 1, pp. 28–41, 2011. View at Publisher · View at Google Scholar · View at Scopus
  57. S. N. Brosius, A. N. Turk, S. J. Byer et al., “Neuregulin-1 overexpression and Trp53 haploinsufficiency cooperatively promote de novo malignant peripheral nerve sheath tumor pathogenesis,” Acta Neuropathologica, vol. 127, no. 4, pp. 573–591, 2014. View at Publisher · View at Google Scholar · View at Scopus
  58. S. Imaizumi, T. Motoyama, A. Ogose, T. Hotta, and H. E. Takahashi, “Characterization and chemosensitivity of two human malignant peripheral nerve sheath tumour cell lines derived from a patient with neurofibromatosis type 1,” Virchows Archiv, vol. 433, no. 5, pp. 435–441, 1998. View at Publisher · View at Google Scholar · View at Scopus
  59. Y. Hirokawa, H. Nakajima, C. O. Hanemann et al., “Signal therapy of NF1-deficient tumor xenograft in mice by the anti-PAK1 drug FK228,” Cancer Biology and Therapy, vol. 4, no. 4, pp. 379–381, 2005. View at Google Scholar · View at Scopus
  60. B. Barkan, S. Starinsky, E. Friedman, R. Stein, and Y. Kloog, “The Ras inhibitor farnesylthiosalicylic acid as a potential therapy for neurofibromatosis type 1,” Clinical Cancer Research, vol. 12, no. 18, pp. 5533–5542, 2006. View at Publisher · View at Google Scholar · View at Scopus
  61. G. Johansson, Y. Y. Mahller, M. H. Collins et al., “Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors,” Molecular Cancer Therapeutics, vol. 7, no. 5, pp. 1237–1245, 2008. View at Publisher · View at Google Scholar · View at Scopus
  62. M. P. Ghadimi, E. D. Young, R. Belousov et al., “Survivin is a viable target for the treatment of malignant peripheral nerve sheath tumors,” Clinical Cancer Research, vol. 18, no. 9, pp. 2545–2557, 2012. View at Publisher · View at Google Scholar · View at Scopus
  63. W. Wang, W. Lin, B. Hong et al., “Effect of triptolide on malignant peripheral nerve sheath tumours in vitro and in vivo,” Journal of International Medical Research, vol. 40, no. 6, pp. 2284–2294, 2012. View at Publisher · View at Google Scholar · View at Scopus
  64. J. Ohishi, M. Aoki, K. Nabeshima et al., “Imatinib mesylate inhibits cell growth of malignant peripheral nerve sheath tumors in vitro and in vivo through suppression of PDGFR-β,” BMC Cancer, vol. 13, article 224, 2013. View at Publisher · View at Google Scholar · View at Scopus
  65. P. P. Patwardhan, O. Surriga, M. J. Beckman et al., “Sustained inhibition of receptor tyrosine kinases and macrophage depletion by PLX3397 and rapamycin as a potential new approach for the treatment of MPNSTs,” Clinical Cancer Research, vol. 20, no. 12, pp. 3146–3158, 2014. View at Publisher · View at Google Scholar · View at Scopus
  66. G. Lopez, K. L. J. Bill, H. K. Bid et al., “HDAC8, A potential therapeutic target for the treatment of malignant peripheral nerve sheath tumors (MPNST),” PLoS ONE, vol. 10, no. 7, Article ID e0133302, 2015. View at Publisher · View at Google Scholar · View at Scopus
  67. P. Zhang, X. Yang, X. Ma et al., “Antitumor effects of pharmacological EZH2 inhibition on malignant peripheral nerve sheath tumor through the miR-30a and KPNB1 pathway,” Molecular Cancer, vol. 14, no. 1, article 55, 2015. View at Publisher · View at Google Scholar · View at Scopus
  68. D. R. Deyle, D. Z. Escobar, K.-W. Peng, and D. Babovic-Vuksanovic, “Oncolytic measles virus as a novel therapy for malignant peripheral nerve sheath tumors,” Gene, vol. 565, no. 1, pp. 140–145, 2015. View at Publisher · View at Google Scholar · View at Scopus
  69. A. R. Maldonado, C. Klanke, A. G. Jeßgga et al., “Molecular engineering and validation of an oncolytic herpes simplex virus type 1 transcriptionally targeted to midkine-positive tumors,” Journal of Gene Medicine, vol. 12, no. 7, pp. 613–623, 2010. View at Publisher · View at Google Scholar · View at Scopus
  70. Y. Y. Mahller, S. S. Vaikunth, M. C. Ripberger et al., “Tissue inhibitor of metalloproteinase-3 via oncolytic herpesvirus inhibits tumor growth and vascular progenitors,” Cancer Research, vol. 68, no. 4, pp. 1170–1179, 2008. View at Publisher · View at Google Scholar · View at Scopus
  71. T.-C. Liu, T. Zhang, H. Fukuhara et al., “Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors,” Clinical Cancer Research, vol. 12, no. 22, pp. 6791–6799, 2006. View at Publisher · View at Google Scholar · View at Scopus
  72. Y. Takamiya, R. M. Friedlander, H. Brem, A. Malick, and R. L. Martuza, “Inhibition of angiogenesis and growth of human nerve-sheath tumors by AGM- 1470,” Journal of Neurosurgery, vol. 78, no. 3, pp. 470–476, 1993. View at Publisher · View at Google Scholar · View at Scopus
  73. J. Castellsagué, B. Gel, J. Fernández-Rodríguez et al., “Comprehensive establishment and characterization of orthoxenograft mouse models of malignant peripheral nerve sheath tumors for personalized medicine,” EMBO Molecular Medicine, vol. 7, no. 5, pp. 608–627, 2015. View at Publisher · View at Google Scholar · View at Scopus
  74. T. De Raedt, Z. Walton, J. L. Yecies et al., “Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors,” Cancer Cell, vol. 20, no. 3, pp. 400–413, 2011. View at Publisher · View at Google Scholar · View at Scopus
  75. R. Lock, R. Ingraham, O. Maertens et al., “Cotargeting MNK and MEK kinases induces the regression of NF1-mutant cancers,” Journal of Clinical Investigation, vol. 126, no. 6, pp. 2181–2190, 2016. View at Publisher · View at Google Scholar · View at Scopus
  76. C. F. Malone, J. A. Fromm, O. Maertens, T. DeRaedt, R. Ingraham, and K. Cichowski, “Defining key signaling nodes and therapeutic biomarkers in NF1-mutant cancers,” Cancer Discovery, vol. 4, no. 9, pp. 1062–1073, 2014. View at Publisher · View at Google Scholar · View at Scopus
  77. K. Cichowski, T. S. Shih, E. Schmitt et al., “Mouse models of tumor development in neurofibromatosis type 1,” Science, vol. 286, no. 5447, pp. 2172–2176, 1999. View at Publisher · View at Google Scholar · View at Scopus
  78. K. S. Vogel, L. J. Klesse, S. Velasco-Miguel, K. Meyers, E. J. Rushing, and L. F. Parada, “Mouse tumor model for neurofibromatosis type 1,” Science, vol. 286, no. 5447, pp. 2176–2179, 1999. View at Publisher · View at Google Scholar · View at Scopus
  79. N. M. Joseph, J. T. Mosher, J. Buchstaller et al., “The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells,” Cancer Cell, vol. 13, no. 2, pp. 129–140, 2008. View at Publisher · View at Google Scholar · View at Scopus
  80. V. W. Keng, E. P. Rahrmann, A. L. Watson et al., “PTEN and NF1 inactivation in Schwann cells produces a severe phenotype in the peripheral nervous system that promotes the development and malignant progression of peripheral nerve sheath tumors,” Cancer Research, vol. 72, no. 13, pp. 3405–3413, 2012. View at Publisher · View at Google Scholar · View at Scopus
  81. J. Wu, D. M. Patmore, E. Jousma et al., “EGFR-STAT3 signaling promotes formation of malignant peripheral nerve sheath tumors,” Oncogene, vol. 33, no. 2, pp. 173–180, 2014. View at Publisher · View at Google Scholar · View at Scopus
  82. C. Gregorian, J. Nakashima, S. M. Dry et al., “PTEN dosage is essential for neurofibroma development and malignant transformation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 46, pp. 19479–19484, 2009. View at Publisher · View at Google Scholar · View at Scopus
  83. V. W. Keng, A. L. Watson, E. P. Rahrmann et al., “Conditional inactivation of Pten with EGFR overexpression in Schwann cells models sporadic MPNST,” Sarcoma, vol. 2012, Article ID 620834, 12 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  84. E. P. Rahrmann, B. S. Moriarity, G. M. Otto et al., “Trp53 haploinsufficiency modifies EGFR-driven peripheral nerve sheath tumorigenesis,” American Journal of Pathology, vol. 184, no. 7, pp. 2082–2098, 2014. View at Publisher · View at Google Scholar · View at Scopus
  85. S. J. Kazmi, S. J. Byer, J. M. Eckert et al., “Transgenic mice overexpressing neuregulin-1 model neurofibroma-malignant peripheral nerve sheath tumor progression and implicate specific chromosomal copy number variations in tumorigenesis,” American Journal of Pathology, vol. 182, no. 3, pp. 646–667, 2013. View at Publisher · View at Google Scholar · View at Scopus
  86. R. D. Dodd, J. K. Mito, W. C. Eward et al., “NF1 deletion generates multiple subtypes of soft-tissue sarcoma that respond to mek inhibition,” Molecular Cancer Therapeutics, vol. 12, no. 9, pp. 1906–1917, 2013. View at Publisher · View at Google Scholar · View at Scopus
  87. A. C. Hirbe, S. Dahiya, D. Friedmann-Morvinski, I. M. Verma, D. Wade Clapp, and D. H. Gutmann, “Spatially- and temporally-controlled postnatal p53 knockdown cooperates with embryonic Schwann cell precursor Nf1 gene loss to promote malignant peripheral nerve sheath tumor formation,” Oncotarget, vol. 7, no. 7, pp. 7403–7414, 2016. View at Publisher · View at Google Scholar · View at Scopus
  88. C.-C. H. Stucky, K. N. Johnson, R. J. Gray et al., “Malignant Peripheral Nerve Sheath Tumors (MPNST): The Mayo Clinic experience,” Annals of Surgical Oncology, vol. 19, no. 3, pp. 878–885, 2012. View at Publisher · View at Google Scholar · View at Scopus
  89. W. W. Wong, T. Hirose, B. W. Scheithauer, S. E. Schild, and L. L. Gunderson, “Malignant peripheral nerve sheath tumor: analysis of treatment outcome,” International Journal of Radiation Oncology Biology Physics, vol. 42, no. 2, pp. 351–360, 1998. View at Publisher · View at Google Scholar · View at Scopus
  90. A. Kaushal and D. Citrin, “The role of radiation therapy in the management of sarcomas,” Surgical Clinics of North America, vol. 88, no. 3, pp. 629–646, 2008. View at Publisher · View at Google Scholar · View at Scopus
  91. J. C. Yang, A. E. Chang, A. R. Baker et al., “Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity,” Journal of Clinical Oncology, vol. 16, no. 1, pp. 197–203, 1998. View at Publisher · View at Google Scholar · View at Scopus
  92. J. Kahn, A. Gillespie, M. Tsokos et al., “Radiation therapy in management of sporadic and neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors,” Frontiers in Oncology, vol. 4, article 324, 2014. View at Publisher · View at Google Scholar · View at Scopus
  93. A. Ferrari, R. Miceli, A. Rey et al., “Non-metastatic unresected paediatric non-rhabdomyosarcoma soft tissue sarcomas: results of a pooled analysis from United States and European groups,” European Journal of Cancer, vol. 47, no. 5, pp. 724–731, 2011. View at Publisher · View at Google Scholar · View at Scopus
  94. M. Carli, A. Ferrari, A. Mattke et al., “Pediatric malignant peripheral nerve sheath tumor: the Italian and German soft tissue sarcoma cooperative group,” Journal of Clinical Oncology, vol. 23, no. 33, pp. 8422–8430, 2005. View at Publisher · View at Google Scholar · View at Scopus
  95. B. C. Widemann, D. K. Reinke, L. J. Helman et al., “SARC006: Phase II trial of chemotherapy in sporadic and neurofibromatosis type 1 (NF1)-associated high-grade malignant peripheral nerve sheath tumors (MPNSTs),” Journal of Clinical Oncology, vol. 31, Article ID 10522, 2013. View at Google Scholar
  96. K. Albritton, C. Rankin, C. M. Coffin et al., “Phase II trial of erlotinib in metastatic or unresectable malignant peripheral nerve sheath tumor (MPNST),” Journal of Clinical Oncology, vol. 24, Article ID 9518, 2006. View at Google Scholar
  97. R. G. Maki, D. R. D'Adamo, M. L. Keohan et al., “Phase II study of sorafenib in patients with metastatic or recurrent sarcomas,” Journal of Clinical Oncology, vol. 27, no. 19, pp. 3133–3140, 2009. View at Publisher · View at Google Scholar
  98. R. Chugh, J. K. Wathen, R. G. Maki et al., “Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model,” Journal of Clinical Oncology, vol. 27, no. 19, pp. 3148–3153, 2009. View at Publisher · View at Google Scholar
  99. S. Schuetze, K. Wathen, E. Choy et al., “Results of a Sarcoma Alliance for Research through Collaboration (SARC) phase II trial of dasatinib in previously treated, high-grade, advanced sarcoma,” Journal of Clinical Oncology, vol. 28, Article ID 10009, 2010. View at Google Scholar
  100. M. A. Dickson, M. R. Mahoney, W. D. Tap et al., “Phase II study of MLN8237 (Alisertib) in advanced/metastatic sarcoma,” Annals of Oncology, vol. 27, no. 10, pp. 1855–1860, 2016. View at Publisher · View at Google Scholar
  101. A. B. Miller, B. Hoogstraten, M. Staquet, and A. Winkler, “Reporting results of cancer treatment,” Cancer, vol. 47, no. 1, pp. 207–214, 1981. View at Publisher · View at Google Scholar · View at Scopus
  102. E. A. Eisenhauer, P. Therasse, J. Bogaerts et al., “New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1),” European Journal of Cancer, vol. 45, no. 2, pp. 228–247, 2009. View at Publisher · View at Google Scholar · View at Scopus
  103. H. Choi, C. Charnsangavej, S. C. Faria et al., “Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria,” Journal of Clinical Oncology, vol. 25, no. 13, pp. 1753–1759, 2007. View at Publisher · View at Google Scholar · View at Scopus
  104. D. Katz, A. Lazar, and D. Lev, “Malignant peripheral nerve sheath tumour (MPNST): the clinical implications of cellular signalling pathways,” Expert Reviews in Molecular Medicine, vol. 11, article e30, 2009. View at Publisher · View at Google Scholar · View at Scopus